Navigation Links
Starpharma and Elanco Sign Agreement
Date:5/11/2009

MELBOURNE, Australia, May 11 /PRNewswire/ -- Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced the signing of a collaborative research, license and commercialisation agreement with Elanco, the animal health division of US pharmaceutical company Eli Lilly and Company.

The parties will collaborate to develop new animal health products with enhanced properties using Starpharma's dendrimer technology. Under the agreement, Starpharma will receive revenue from research fees, and is eligible for milestone payments and royalties on sale of any product developed. Elanco will receive exclusivity within the animal health field. Terms were not disclosed.

"We are very pleased to have secured such a strong animal health partner as Elanco for our delivery technology," said Dr Jackie Fairley, CEO, Starpharma.

"Their expertise, resources and market presence will be enormously valuable assets as we work to bring these innovative products to market," Fairley said. "An exciting aspect of this application for our business is that product development in the animal health sector can be faster than is usually associated with the development of human drugs."

The collaboration with Elanco is further demonstration of Starpharma's strong and successful partnership model and the multiple potential applications of its dendrimer technology. Starpharma also has partnerships with SSL International (Durex(R)), Siemens (Dade Behring), EMD Merck, Stiefel, Unilever, Qiagen and Sigma Aldrich.

Starpharma retains all rights to exploit the technology outside of Elanco's specific field of interest, including for all uses in humans, and continues to work to add to its portfolio of partners for drug delivery and dendrimer technology more widely.

In 2008, the global animal health market was reported to be about US$19 billion. Global sales are expected to reach US$21.7B by 2010, at which time the top three markets are forecast to be USA, China and Brazil, with the USA accounting for 40 percent of growth [1].

About Starpharma

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL has two operating companies, Starpharma Pty Ltd in Melbourne, Australia and DNT, Inc in the USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents through licence arrangements with partners including Siemens and Merck KgA.

    For further information:

       Media
       Buchan Consulting
       Rebecca Wilson
       Tel: +61 3 9866 4722
       Mob: +61 417 382 391
       rwilson@bcg.com.au

       Ellie Papathanasiou
       Tel: +61 2 9237 2800
       epapathanasiou@bcg.com.au

       Starpharma
       www.starpharma.com
       Dr Jackie Fairley
       Chief Executive Officer
       +61 3 8532 2704

       Ben Rogers
       Company Secretary
       +61 3 8532 2702
       ben.rogers@starpharma.com

[1]Vetnosis for global animal health market estimate; all other information in "World Animal Health Markets" from Informa Healthcare, January 2008.


'/>"/>
SOURCE Starpharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Starpharma and Durex Sign Co-Development Agreement for VivaGel(R)-Coated Condoms
2. Heifer and Elanco Announce Charitable Partnership
3. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
4. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
5. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
6. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
7. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
8. RNs at Nine Catholic Healthcare West Hospitals Reach Agreement on New Master Pact
9. WellPoint and M-Plan Enter Into Endorsement Agreement as M-Plan Announces Exit From the Commercial HMO Business in Indiana
10. Biomoda, Inc. and Quintiles Announce Agreement for Regulatory Consulting
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... Bellus Medical, ... latest innovation in the delivery of Platelet Rich Plasma (PRP). PRP systems are ... management, to accelerate tissue synthesis and provide a faster and more efficient healing ...
(Date:2/22/2017)... Athens, GA (PRWEB) , ... February 22, 2017 , ... ... Feb. 25 and 26 event in Athens, Georgia. , A shift from Super-Sod’s simple ... made in Georgia. , For the booth, grass seed plant manager Chris Roquemore constructed ...
(Date:2/22/2017)... ... February 22, 2017 , ... In ... many different solutions on the market, it is easy to start feeling frustrated ... Locksmith offers a complimentary security consultation. , Home Security Hardware Choices, There ...
(Date:2/21/2017)... Australia (PRWEB) , ... February 22, 2017 , ... Author ... it is valuable for every household and family to know all about it for ... publishing world with the release of “ Detox, Digestive and Wellness Solutions ” (published ...
(Date:2/21/2017)... ... February 21, 2017 , ... As recently as 2015, rhinoplasty was one of ... of Plastic Surgeons. Some patients want to make a change in the appearance of ... their breathing ability. The team at usrhinoplasty.org is expanding its article database ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... 2017  Applied Silver, the maker of SilvaClean®, today announced ... advisory board. Ms. Barnes is the company,s third Clinical Advisor ... and healthcare experts Scott McNealy , Josh McQueen ... J. Tress Ritter , and Leopold Selker . ... than three decades of nationally recognized clinical, nursing, and infection ...
(Date:2/22/2017)... Feb. 22, 2017 Oncternal Therapeutics, Inc., ... both rare and common malignancies, today announced the ... The company intends to use the proceeds to ... and to advance preclinical development of a new ... is a first-in-class anti-ROR1 monoclonal antibody being developed ...
(Date:2/22/2017)... BEACH, Florida , February 22, 2017 /PRNewswire/ ... Cannabis Industries is becoming more and more prevalent ... Of Cannabinoids & THC Extracts as well as ... approach to medicinal cannabis and marijuana therapies and ... acquiring new relationships and assets designed to bring ...
Breaking Medicine Technology: